Neuroprotective Effects of Protocatechuic Aldehyde against Neurotoxin-Induced Cellular and Animal Models of Parkinson's Disease

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Zhao, Xin ^a,b   Zhai, Shenyu ^c   An, Ming Sheng ^a,b   Wang, Yue Hua ^b,d   Yang, Ying Fan ^a,b   Ge, Hui Qi ^a,b   Liu, Jin Hao ^a,b   Pu, Xiao Ping ^a,b  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; DJ 1 PROTEIN; DOPAMINE; NEUROTOXIN; OXIDOPAMINE; PROTOCATECHUALDEHYDE; REACTIVE OXYGEN METABOLITE; BENZALDEHYDE DERIVATIVE; CATECHOL DERIVATIVE; NEUROPROTECTIVE AGENT; ONCOPROTEIN;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CELL VIABILITY; CONTROLLED STUDY; CORPUS STRIATUM; DENSITY; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; HIPPOCAMPAL CA1 REGION; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOTOR COORDINATION; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATION REDUCTION REACTION; PARKINSON DISEASE; PC12 CELL; PROTEIN EXPRESSION; RAT; SPINE DENSITY; SUBSTANTIA NIGRA; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PC12 CELL LINE; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ALPHA-SYNUCLEIN; ANIMALS; BENZALDEHYDES; CATECHOLS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINERGIC NEURONS; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; NEUROTOXINS; ONCOGENE PROTEINS; PARKINSON DISEASE; PC12 CELLS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SUBSTANTIA NIGRA;

EID: 84885759007     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078220     Document Type: Article

References (59)

1. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, et al. (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68: 384-386. doi:10.1212/01.wnl.0000247740.47667.03. PubMed: 17082464.
2. Thomas B, Beal MF, (2007) Parkinson's disease. Hum Mol Genet 16spec No. 2:: R183-R194.
3. Takahashi-Niki K, Niki T, Taira T, Iguchi-Ariga SM, Ariga H, (2004) Reduced anti-oxidative stress activities of DJ-1 mutants found in Parkinson's disease patients. Biochem Biophys Res Commun 320: 389-397. doi:10.1016/j.bbrc.2004.05.187. PubMed: 15219840.
4. Clements CM, McNally RS, Conti BJ, Mak TW, Ting JP, (2006) DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci U S A 103: 15091-15096. doi:10.1073/pnas.0607260103. PubMed: 17015834.
5. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, et al. (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299: 256-259. doi:10.1126/science.1077209. PubMed: 12446870.
6. Takahashi K, Taira T, Niki T, Seino C, Iguchi-Ariga SM, et al. (2001) DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptor. J Biol Chem 276: 37556-37563. doi:10.1074/jbc.M101730200. PubMed: 11477070.
7. Ottolini D, Cali T, Negro A, Brini M, (2013) The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum-mitochondria tethering. Hum: Mol Genet.
8. Schnabel J, (2010) Secrets of the shaking palsy. Nature 466: S2-S5. doi:10.1038/466S2b. PubMed: 20739933.
9. Khan W, Priyadarshini M, Zakai HA, Kamal MA, Alam Q, (2012) A brief overview of tyrosine hydroxylase and alpha-synuclein in the Parkinsonian brain. CNS Neurol Disord Drug Targets 11: 456-462. doi:10.2174/187152712800792929. PubMed: 22583430.
10. Moon CY, Ku CR, Cho YH, Lee EJ, (2012) Protocatechuic aldehyde inhibits migration and proliferation of vascular smooth muscle cells and intravascular thrombosis. Biochem Biophys Res Commun 423: 116-121. doi:10.1016/j.bbrc.2012.05.092. PubMed: 22640742.
11. Xing YL, Zhou Z, Agula, Zhong ZY, Ma YJ, et al. (2012) Protocatechuic Aldehyde Inhibits Lipopolysaccharide-induced Human Umbilical Vein Endothelial Cell Apoptosis via Regulation of Caspase-3. Phytother Res, 26: 1334-41. PubMed: 22298410.
12. Li C, Jiang W, Zhu H, Hou J, (2012) Antifibrotic effects of protocatechuic aldehyde on experimental liver fibrosis. Pharm Biol 50: 413-419. doi:10.3109/13880209.2011.608193. PubMed: 22129045.
13. Xu Y, Jiang WL, Zhang SP, Zhu HB, Hou J, (2012) Protocatechuic aldehyde protects against experimental sepsis in vitro and in vivo. Basic Clin Pharmacol Toxicol 110: 384-389. doi:10.1111/j.1742-7843.2011.00827.x. PubMed: 22050905.
14. Zhou Z, Zhang Y, Ding XR, Chen SH, Yang J, et al. (2007) Protocatechuic aldehyde inhibits hepatitis B virus replication both in vitro and in vivo. Antiviral Res 74: 59-64. doi:10.1016/j.antiviral.2007.01.086. PubMed: 17298850.
15. Chang ZQ, Gebru E, Lee SP, Rhee MH, Kim JC, et al. (2011) In vitro antioxidant and anti-inflammatory activities of protocatechualdehyde isolated from Phellinus gilvus. J Nutr Sci Vitaminol (Tokyo) 57: 118-122. doi:10.3177/jnsv.57.118.
16. Gao JW, Yamane T, Maita H, Ishikawa S, Iguchi-Ariga SM, et al. (2011) DJ-1-Mediated protective effect of protocatechuic aldehyde against oxidative stress in SH-SY5Y cells. J Pharmacol Sci 115: 36-44. doi:10.1254/jphs.10271FP. PubMed: 21160133.
17. Zhang SP, Du XG, Pu XP, (2010) 3-O-demethylswertipunicoside protects against oxidative toxicity in PC12 cells. Biol Pharm Bull 33: 1529-1533. doi:10.1248/bpb.33.1529. PubMed: 20823569.
18. Sun SY, An CN, Pu XP, (2012) DJ-1 protein protects dopaminergic neurons against 6-OHDA/MG-132-induced neurotoxicity in rats. Brain. Res Bull 88: 609-616. doi:10.1016/j.brainresbull.2012.05.013.
19. Zhao X, Li Q, Zhao L, Pu X, (2007) Proteome analysis of substantia nigra and striatal tissue in the mouse MPTP model of Parkinson's disease. Proteomics Clin Appl 1: 1559-1569. doi:10.1002/prca.200700077. PubMed: 21136655.
20. Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, et al. (1999) Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl) 147: 90-95. doi:10.1007/s002130051146.
21. Li S, Pu XP, (2011) Neuroprotective effect of kaempferol against a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease. Biol Pharm Bull 34: 1291-1296. doi:10.1248/bpb.34.1291. PubMed: 21804220.
22. Kim ST, Son HJ, Choi JH, Ji IJ, Hwang O, (2010) Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease. Brain Res 1306: 176-183. doi:10.1016/j.brainres.2009.09.103. PubMed: 19804765.
23. Stoppini L, Buchs PA, Muller D, (1991) A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 37: 173-182. doi:10.1016/0165-0270(91)90128-M. PubMed: 1715499.
24. O'Brien JA, Lummis SC, (2006) Biolistic transfection of neuronal cultures using a hand-held gene gun. Nat Protoc 1: 977-981. doi:10.1038/nprot.2006.145. PubMed: 17406333.
25. Zhou W, Bercury K, Cummiskey J, Luong N, Lebin J, et al. (2011) Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease. J Biol Chem 286: 14941-14951. doi:10.1074/jbc.M110.211029. PubMed: 21372141.
26. Purisai MG, McCormack AL, Langston WJ, Johnston LC, Di Monte DA, (2005) Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol Dis 20: 898-906. doi:10.1016/j.nbd.2005.05.028. PubMed: 16006134.
27. Lev N, Ickowicz D, Barhum Y, Lev S, Melamed E, et al. (2009) DJ-1 protects against dopamine toxicity. J Neural Transm 116: 151-160. doi:10.1007/s00702-008-0134-4. PubMed: 18974921.
28. Batelli S, Albani D, Rametta R, Polito L, Prato F, et al. (2008) DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70. PLOS ONE 3: e1884. doi:10.1371/journal.pone.0001884. PubMed: 18382667.
29. Poewe W, (2009) Treatments for Parkinson disease--past achievements and current clinical needs. Neurology 72: S65-S73. doi:10.1212/01.wnl.0000345661.85492.6b. PubMed: 19221317.
30. Du F, Qian ZM, Zhu L, Wu XM, Yung WH, et al. (2009) L-DOPA neurotoxicity is mediated by up-regulation of DMT1-IRE expression. PLOS ONE 4: e4593. doi:10.1371/journal.pone.0004593. PubMed: 19240805.
31. Satoh T, Sakai N, Enokido Y, Uchiyama Y, Hatanaka H, (1996) Free radical-independent protection by nerve growth factor and Bcl-2 of PC12 cells from hydrogen peroxide-triggered apoptosis. J Biochem 120: 540-546. doi:10.1093/oxfordjournals.jbchem.a021447. PubMed: 8902618.
32. Lin E, Cavanaugh JE, Leak RK, Perez RG, Zigmond MJ, (2008) Rapid activation of ERK by 6-hydroxydopamine promotes survival of dopaminergic cells. J Neurosci Res 86: 108-117. doi:10.1002/jnr.21478. PubMed: 17847117.
33. Rebois RV, Reynolds EE, Toll L, Howard BD, (1980) Storage of dopamine and acetylcholine in granules of PC12, a clonal pheochromocytoma cell line. Biochemistry 19: 1240-1248. doi:10.1021/bi00547a031. PubMed: 7370231.
34. Wang YH, Xuan ZH, Tian S, He GR, Du GH, (2013) Myricitrin attenuates 6-hydroxydopamine-induced mitochondrial damage and apoptosis in PC12 cells via inhibition of mitochondrial oxidation. J Funct Foods 5: 337-345. doi:10.1016/j.jff.2012.11.004.
35. Blesa J, Phani S, Jackson-Lewis V, Przedborski S, (2012) Classic and new animal models of Parkinson's disease. J Biomed Biotechnol, 2012(2012): 845618. PubMed: 22536024.
36. Dauer W, Przedborski S, (2003) Parkinson's disease: mechanisms and models. Neuron 39: 889-909. doi:10.1016/S0896-6273(03)00568-3. PubMed: 12971891.
37. Paterna JC, Leng A, Weber E, Feldon J, Büeler H, (2007) DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice. Mol Ther 15: 698-704. PubMed: 17299411.
38. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839-840. doi:10.1038/42166. PubMed: 9278044.
39. Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, et al. (2000) Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem 74: 721-729. PubMed: 10646524.
40. Liu F, Nguyen JL, Hulleman JD, Li L, Rochet JC, (2008) Mechanisms of DJ-1 neuroprotection in a cellular model of Parkinson's disease. J Neurochem 105: 2435-2453. doi:10.1111/j.1471-4159.2008.05333.x. PubMed: 18331584.
41. Tang B, Xiong H, Sun P, Zhang Y, Wang D, et al. (2006) Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. Hum Mol Genet 15: 1816-1825. doi:10.1093/hmg/ddl104. PubMed: 16632486.
42. Zaja-Milatovic S, Milatovic D, Schantz AM, Zhang J, Montine KS, et al. (2005) Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology 64: 545-547. doi:10.1212/01.WNL.0000150591.33787.A4. PubMed: 15699393.
43. Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, et al. (1995) Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 16: 285-304; discussion: 7566338.
44. Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, et al. (1997) Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol 56: 933-944. doi:10.1097/00005072-199708000-00011. PubMed: 9258263.
45. Soderstrom KE, O'Malley JA, Levine ND, Sortwell CE, Collier TJ, et al. (2010) Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian rats. Eur J Neurosci 31: 478-490. doi:10.1111/j.1460-9568.2010.07077.x. PubMed: 20105237.
46. Smith DL, Pozueta J, Gong B, Arancio O, Shelanski M, (2009) Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc Natl Acad Sci U S A 106: 16877-16882. doi:10.1073/pnas.0908706106. PubMed: 19805389.
47. Beyer MK, Bronnick KS, Hwang KS, Bergsland N, Tysnes OB, et al. (2013) Verbal memory is associated with structural hippocampal changes in newly diagnosed Parkinson's disease. J Neurol Neurosurg, Psychiatry 84: 23-28. doi:10.1136/jnnp-2012-303054. PubMed: 23154124.
48. Brück A, Kurki T, Kaasinen V, Vahlberg T, Rinne JO, (2004) Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson's disease is related to cognitive impairment. J Neurol Neurosurg, Psychiatry 75: 1467-1469. doi:10.1136/jnnp.2003.031237.
49. Camicioli R, Moore MM, Kinney A, Corbridge E, Glassberg K, et al. (2003) Parkinson's disease is associated with hippocampal atrophy. Mov Disord 18: 784-790. doi:10.1002/mds.10444. PubMed: 12815657.
50. Carlesimo GA, Piras F, Assogna F, Pontieri FE, Caltagirone C, et al. (2012) Hippocampal abnormalities and memory deficits in Parkinson disease: a multimodal imaging study. Neurology 78: 1939-1945. doi:10.1212/WNL.0b013e318259e1c5. PubMed: 22649213.
51. Galvin JE, Uryu K, Lee VM, Trojanowski JQ, (1999) Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc Natl Acad Sci U S A 96: 13450-13455. doi:10.1073/pnas.96.23.13450. PubMed: 10557341.
52. Weintraub D, et al DJKD,. (2011) NEurodegeneration across stages of cognitive decline in parkinson disease. Arch Neurol 68: 1562-1568. doi:10.1001/archneurol.2011.725. PubMed: 22159053.
53. Ingham CA, Hood SH, Arbuthnott GW, (1989) Spine density on neostriatal neurones changes with 6-hydroxydopamine lesions and with age. Brain Res 503: 334-338. doi:10.1016/0006-8993(89)91686-7. PubMed: 2514009.
54. Day M, Wang Z, Ding J, An X, Ingham CA, et al. (2006) Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci 9: 251-259. doi:10.1038/nn1632. PubMed: 16415865.
55. Soderstrom KE, O'Malley JA, Levine ND, Sortwell CE, Collier TJ, et al. (2010) Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian rats. Eur J Neurosci 31: 478-490. doi:10.1111/j.1460-9568.2010.07077.x. PubMed: 20105237.
56. Stephens B, Mueller AJ, Shering AF, Hood SH, Taggart P, et al. (2005) Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience 132: 741-754. doi:10.1016/j.neuroscience.2005.01.007. PubMed: 15837135.
57. Li Z, Okamoto K-I, Hayashi Y, Sheng M, (2004) The Importance of Dendritic Mitochondria in the Morphogenesis and Plasticity of Spines and Synapses. Cell 119: 873-887. doi:10.1016/j.cell.2004.11.003. PubMed: 15607982.
58. Perez-Cruz C, Nolte MW, van Gaalen MM, Rustay NR, Termont A, et al. (2011) Reduced spine density in specific regions of CA1 pyramidal neurons in two transgenic mouse models of Alzheimer's disease. J Neurosci 31: 3926-3934. doi:10.1523/JNEUROSCI.6142-10.2011. PubMed: 21389247.
59. Tyler WJ, Pozzo-Miller L, (2003) Miniature synaptic transmission and BDNF modulate dendritic spine growth and form in rat CA1 neurones. J Physiol 553: 497-509. doi:10.1113/jphysiol.2003.052639. PubMed: 14500767.